Van ECK Associates Corp Has $114.01 Million Stock Position in Johnson & Johnson $JNJ

Van ECK Associates Corp lowered its stake in Johnson & Johnson (NYSE:JNJ) by 28.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 614,882 shares of the company’s stock after selling 246,677 shares during the period. Van ECK Associates Corp’s holdings in Johnson & Johnson were worth $114,011,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. SOA Wealth Advisors LLC. raised its stake in Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after acquiring an additional 53 shares in the last quarter. Ethos Financial Group LLC boosted its stake in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after purchasing an additional 53 shares during the last quarter. Pinnacle Holdings LLC grew its holdings in Johnson & Johnson by 0.5% during the 3rd quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock worth $2,079,000 after acquiring an additional 54 shares during the period. Bouchey Financial Group Ltd increased its holdings in Johnson & Johnson by 0.8% in the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock worth $1,344,000 after purchasing an additional 54 shares in the last quarter. Finally, Heritage Oak Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 3.5% during the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after acquiring an additional 55 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE JNJ opened at $243.75 on Wednesday. The company has a market cap of $587.41 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm’s 50-day simple moving average is $229.80 and its two-hundred day simple moving average is $205.27. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Analysts Set New Price Targets

A number of research analysts have weighed in on JNJ shares. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Wolfe Research raised their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $234.87.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock worth $7,360,528 in the last 90 days. Company insiders own 0.16% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approvals bolster commercial and clinical growth runway for oncology/immunotherapy — the TECVAYLI (teclistamab) + DARZALEX FASPRO approval opens a newer immune‑engaging combo for relapsed/refractory multiple myeloma that could shift treatment into earlier lines and meaningfully increase oncology sales upside. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU label expansion for Akeega (prostate cancer) increases market opportunity in BRCA‑mutated metastatic hormone‑sensitive prostate cancer — supports future oncology revenue and pipeline leverage in targeted therapies. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Company presentation / transcript at Barclays healthcare conference provides management color on strategy/execution; useful for analysts but contains no surprise guidance that would immediately change valuations. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/coverage pieces and valuation reviews have brought JNJ back onto investor radars after recent rallies; helpful context for longer‑term positioning but not an immediate catalyst. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Neutral Sentiment: Industry/competitive articles (e.g., on Hologic) highlight device market dynamics that could inform med‑tech positioning; monitor for share gains/losses in specific device categories. What Drives Hologic’s GYN Surgical Strength in a Competitive Market?
• Negative Sentiment: Short interest rose ~20.8% in February (to ~25.1M shares), increasing bearish positioning — could add downward pressure if momentum reverses or sentiment worsens. (internal short‑interest report)
• Negative Sentiment: Two J&J units agreed to pay $65M to settle a Tracleer antitrust class action — a modest cash impact but a headline legal item that slightly offsets positive regulatory news. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.